High materiality7/10
Foghorn Therapeutics downgraded to In Line from Outperform at Evercore ISI
Why it may matterVerify against the original reporting
Upside potential despite the downgrade; target implies significant near-term upside.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target updated to $3; current price $1.95; Evercore ISI.
- Target $3 vs price $1.95; Evercore ISI
Key facts
- 01
Target: $3
- 02
Posted price: $1.95
- 03
Analyst firm: Evercore ISI
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.